Popular Trials
Anti-metabolites
Decitabine for Myelofibrosis
This trial looks at the side effects and effectiveness of decitabine in treating patients with myelofibrosis, a cancer of the blood system. Decitabine may block proteins that turn certain genes off in various cancers including myelofibrosis.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Pacritinib + Talazoparib for Myeloproliferative Disorders
This trial is a study to find the appropriate dosage of talazoparib when given with pacritinib, a standard treatment. The goal is to determine the maximum tolerated dosage and the recommended
Monoclonal Antibodies
Canakinumab for Myelofibrosis
This trial is testing Canakinumab as a treatment for primary myelofibrosis, post essential thrombocythemia/polycythemia vera related MF. Eligible patients will receive Canakinumab administered as a subcutaneous injection every 3 weeks for a core study period of 8 cycles.
Tyrosine Kinase Inhibitor
TL-895 + Ruxolitinib for Myelofibrosis
This trial tests TL-895, a new oral medication, for treating Myelofibrosis, a type of bone marrow cancer. It targets patients who haven't tried certain treatments or didn't respond well to previous medications. TL-895 works by blocking enzymes that help cancer cells grow.
Popular Filters
Trials for Acute Myeloid Leukemia Patients
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Stem Cell Transplant for Lymphoma
This trial looks at a procedure to help patients with graft failure. The procedure uses CD34 selected grafts to reduce risk of graft versus host disease. It is safe & effective & is being tested for malignant & non-malignant conditions.
Trials for Prolymphocytic Leukemia Patients
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Stem Cell Transplant for Lymphoma
This trial looks at a procedure to help patients with graft failure. The procedure uses CD34 selected grafts to reduce risk of graft versus host disease. It is safe & effective & is being tested for malignant & non-malignant conditions.
Phase 3 Trials
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Bromodomain and Extra-Terminal Protein Inhibitor
Pelabresib for Myelofibrosis
This trial tests a new drug combination of pelabresib and ruxolitinib in patients with myelofibrosis who haven't tried certain treatments before. Pelabresib blocks harmful proteins, and ruxolitinib stops harmful signals to see if this combination works better.
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Trials With No Placebo
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Selective Inhibitor of Nuclear Export (SINE)
Selinexor for Myelofibrosis
This trial is testing selinexor, a medication that may help treat certain blood disorders. It focuses on patients with primary or secondary myelofibrosis who do not respond to or cannot tolerate common treatments like ruxolitinib. Selinexor works by blocking a protein that helps harmful cells grow and survive. Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
View More Related Trials
Frequently Asked Questions
Introduction to myelofibrosis
What are the top hospitals conducting myelofibrosis research?
The quest for effective treatments in the battle against myelofibrosis has brought together top hospitals that specialize in clinical trials. Located in New york, the Icahn School of Medicine at Mount Sinai takes the lead with ten ongoing myelofibrosis trials and a total of 20 completed studies since their first recorded trial back in 2007. Meanwhile, The University of Texas MD Anderson Cancer Center in Houston stands out with seven active myelofibrosis trials and a history of eleven previous investigations dating from their inaugural trial in 2011.
Not to be overlooked is the Gabrail Cancer Center, situated in Canton, which currently runs six active myelofibrosis trials while contributing eight all-time studies since its initial experiment conducted back in 2004. Another reputable institution making strides is MD Anderson Cancer Center, also located in Houston, where researchers are conducting six ongoing clinical trials for myelofibrosis while boasting an impressive track record of nineteen previously conducted studies since embarking on this challenging research path. Lastly yet notably significant is Memorial Sloan Kettering Cancer Center based out of New York City; here five vital current explorations coexist alongside twelve past endeavors stretching as far back as 2009 when they recorded their first ever investigation into tackling Myelofibrosis.
Myelofibrosis - a rare bone marrow disorder characterized by abnormal blood cell production leading to scarring within the bone marrow - affects individuals around the globe and demands relentless efforts from medical professionals to improve patient outcomes and quality of life. These top hospitals dedicated to advancing knowledge through clinical research bring renewed hope not only to those directly affected but also shed light on potential breakthroughs that could impact future treatment options globally.
Which are the best cities for myelofibrosis clinical trials?
When it comes to myelofibrosis clinical trials, several cities have emerged as leading destinations for research and advancements in treatment. New york City takes the lead with 43 active trials focused on innovative approaches such as Arm 3: JAKi Naïve Combination Arm, Navitoclax, FEDRATINIB, among others. Houston, Texas follows closely behind with 34 ongoing studies investigating parsaclisib, KRT-232, Navitoclax, and more. Seattle in Washington state has become another prominent hub with 15 active trials exploring Allogeneic Hematopoietic Stem Cell Transplantation, FEDRATINIB, Bomedemstat, and other potential breakthroughs. These cities along with Ann Arbor (Michigan) and Los Angeles (California) offer individuals battling myelofibrosis access to cutting-edge clinical trials that hold promise for improved outcomes and quality of life.
Which are the top treatments for myelofibrosis being explored in clinical trials?
Myelofibrosis, a complex and challenging condition, is currently the focus of several promising treatments in clinical trials. Among the top contenders are:
- Allogeneic Hematopoietic Stem Cell Transplantation with 4 active trials since 2014.
- TL-895 showing potential in 3 ongoing trials following its introduction in 2020.
- Selinexor making headway with 3 active trials since its listing in 2019.
- KRT-232 also gaining attention through its involvement in 3 ongoing studies starting from 2019.
- Navitoclax, entering the scene in 2017, participating in three current myelofibrosis trials. These innovative therapies offer hope for improved outcomes and quality of life for individuals battling this debilitating disease.
What are the most recent clinical trials for myelofibrosis?
Exciting developments are underway in the field of myelofibrosis research, with recent clinical trials exploring potentially groundbreaking treatments. Among these trials is an investigation into reparixin as a potential therapy for myelofibrosis patients. Another trial focuses on the use of pegylated interferon alpha2a to evaluate its efficacy and safety in treating this condition. Additionally, NS-018 is being studied in phase 2 trials to assess its effectiveness against myelofibrosis. The combination of ruxolitinib and abemaciclib is also under examination, aiming to determine if it can provide improved outcomes for individuals with myelofibrosis. Finally, CK0804 has entered phase 1 trials to explore its potential benefits for those affected by this condition. These exciting endeavors hold promise for advancing treatment options and improving the lives of people living with myelofibrosis.
What myelofibrosis clinical trials were recently completed?
Several noteworthy clinical trials for myelofibrosis have recently concluded, representing significant progress in the search for effective treatments. In July 2021, Incyte Corporation successfully completed a trial investigating itacitinib's potential in combating this challenging condition. Additionally, John Mascarenhas wrapped up a trial involving AVID200 in February 2019. Further groundbreaking research includes Celgene's Luspatercept trial completion in November 2017 and Imago BioSciences' IMG-7289 study conclusion in July 2017. These remarkable advancements highlight the unwavering commitment of researchers towards advancing our understanding and management of myelofibrosis.